Cite
HARVARD Citation
Cohen, J. et al. (n.d.). A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma. British journal of haematology. pp. 539-546. [Online].